Alemtuzumab treatment alters circulating innate immune cells in multiple sclerosis. - Wikidata - wikimedia - TriplyDB

Alemtuzumab treatment alters circulating innate immune cells in multiple sclerosis.

Alemtuzumab treatment alters circulating innate immune cells in multiple sclerosis.

http://www.wikidata.org/entity/Q37337775

about

Innate lymphoid cells: major players in inflammatory diseases.Regulatory Functions of Natural Killer Cells in Multiple Sclerosis.Alemtuzumab in the long-term treatment of relapsing-remitting multiple sclerosis: an update on the clinical trial evidence and data from the real world.Drugs approved for the treatment of multiple sclerosis: review of their safety profile.Natural Killer Cells Regulate Th17 Cells After Autologous Hematopoietic Stem Cell Transplantation for Relapsing Remitting Multiple Sclerosis.A case of Alemtuzumab-induced neutropenia in multiple sclerosis in association with the expansion of large granular lymphocytes Clinical pharmacology of alemtuzumab, an anti-CD52 immunomodulator, in multiple sclerosis

P2860

Q38643190-54613103-1EDA-47E0-B955-D3169D319D31 Q39032832-6F79E86C-E340-47A5-900D-F4799F5A75DA Q42361890-A25E5203-7AE9-4F05-BBC5-BB241E9935FB Q47868767-540657E5-A7A1-487F-86D6-54AF8381C6D3 Q54960016-30E894D4-7A2D-4F5F-8646-F5975AC99C06 Q58101281-0E2C100D-1F2E-4F56-90EE-CD47CAEB6CED Q59129976-D70AD495-A85F-44AA-92EE-3B65E2E1DC33

P2860

Alemtuzumab treatment alters circulating innate immune cells in multiple sclerosis.

http://www.wikidata.org/entity/Q37337775

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 12 October 2016

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Alemtuzumab treatment alters circulating innate immune cells in multiple sclerosis.

@en

Alemtuzumab treatment alters circulating innate immune cells in multiple sclerosis.

@nl

type

label

Alemtuzumab treatment alters circulating innate immune cells in multiple sclerosis.

@en

Alemtuzumab treatment alters circulating innate immune cells in multiple sclerosis.

@nl

prefLabel

Alemtuzumab treatment alters circulating innate immune cells in multiple sclerosis.

@en

Alemtuzumab treatment alters circulating innate immune cells in multiple sclerosis.

@nl

P1433

Q37337775-ECDC8C3E-8ED9-45E4-8759-A922949C8279

P1476

Q37337775-4D1842D8-959D-49B5-A089-A5AFD8F6B80B

P2093

Q37337775-0DE61C93-E45E-483F-A81A-2696B97F6EAF

Q37337775-28EBE968-9674-4A0A-9226-04EEDE4CF358

Q37337775-446757C0-E84E-4230-A622-1D506990F541

Q37337775-64A85237-E40C-48E4-A8F0-F7631C76A8B8

Q37337775-68597780-1947-4E74-85E1-0EAFD47D58E5

Q37337775-68E65B8E-0D1A-4E01-A6DF-300E124968F7

Q37337775-7B5A2528-0147-4E45-A255-EA5D36A2F611

Q37337775-84A88D7A-EE32-4606-B934-AF449B6FC0FB

Q37337775-A9970534-89A0-4739-959C-CE8D973A3B2A

Q37337775-E5CFEACC-AF4C-43CF-A5CB-F592ADF7A2B9

P2860

Q37337775-0D823DD7-1880-4BFA-94CE-84F604B03837

Q37337775-1094A06B-A1CF-4672-851F-50001F1BFFE7

Q37337775-165E9B79-DE29-42D7-9184-48F33C08EAB6

Q37337775-1F8F0B5F-55D6-4A6F-A978-7711F8D76EF1

Q37337775-280BD0B9-D80F-46EA-9F91-D75126879730

Q37337775-2D3C6183-F901-484F-A53C-73F6412DD917

Q37337775-328E27DC-7AB8-4352-837A-A2EE8D0A07BF

Q37337775-4070F05C-64F6-4924-B06B-E36D1CF46D8F

Q37337775-432AB148-DBB1-42DB-A93D-7D584DB9FBDA

Q37337775-4A92F955-3D1C-49A8-A0D2-33CE2055C1D6

P304

Q37337775-007837F6-E618-4FFF-84F0-7C58045F9DEE

P31

Q37337775-CB6DB4ED-A63B-4EA7-879A-69E9076D925E

P356

Q37337775-D72DD5AD-2337-4388-A9FD-5B3FD8A33B3F

P433

Q37337775-82BE64CA-AD6B-451E-9138-06891992849D

P478

Q37337775-FC451574-A19D-4FB5-B6FD-3D2CCB616A84

P50

Q37337775-4742D87E-F8FB-4AD5-BAEC-45FD0575F491

Q37337775-6CF0CFD1-8B61-4E21-81F2-B238CDA156D7

Q37337775-8B5C2117-D07E-4796-9DCB-A3E94A80823A

Q37337775-E5308257-626F-40ED-9FAE-ACB5CB6A9C58

P577

Q37337775-DE3DEB12-2913-4B10-B94F-3D616EB9390E

P698

Q37337775-961A1829-7DCC-4562-B00F-67CFFA359583

P921

Q37337775-990ED257-23F8-490A-8207-058A48B616B7

P932

Q37337775-3971F681-B5EE-4A74-9494-FBC3D299B1A0

P356

NXI.0000000000000289

P1433

Neurology(R) neuroimmunology & neuroinflammation

P1476

Alemtuzumab treatment alters circulating innate immune cells in multiple sclerosis.

@en

P2093

Bettina Graefe

http://www.w3.org/2001/XMLSchema#string

Diana Ahmetspahic

http://www.w3.org/2001/XMLSchema#string

Judith Alferink

http://www.w3.org/2001/XMLSchema#string

Kathrin Schwarte

http://www.w3.org/2001/XMLSchema#string

Luisa Klotz

http://www.w3.org/2001/XMLSchema#string

Nico Melzer

http://www.w3.org/2001/XMLSchema#string

Silke Jörgens

http://www.w3.org/2001/XMLSchema#string

Susanne Windhagen

http://www.w3.org/2001/XMLSchema#string

Sven G Meuth

http://www.w3.org/2001/XMLSchema#string

Tobias Ruck

http://www.w3.org/2001/XMLSchema#string

P2860

Alemtuzumab in Multiple Sclerosis: Mechanism of Action and Beyond

Peripheral blood but not tissue dendritic cells express CD52 and are depleted by treatment with alemtuzumab

Development of monocytes, macrophages, and dendritic cells

The role of dendritic cells in autoimmunity

Simultaneous early-onset immune thrombocytopenia and autoimmune thyroid disease following alemtuzumab treatment in relapsing-remitting multiple sclerosis.

The expanding family of innate lymphoid cells: regulators and effectors of immunity and tissue remodeling.

Human peripheral blood mononuclear cells exhibit heterogeneous CD52 expression levels and show differential sensitivity to alemtuzumab mediated cytolysis.

Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis.

Increase in Peripheral CD3-CD56brightCD16- Natural Killer Cells in Hashimoto's Thyroiditis Associated with HHV-6 Infection.

Effects of blood transportation on human peripheral mononuclear cell yield, phenotype and function: implications for immune cell biobanking.

P304

e289

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1212/NXI.0000000000000289

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

3

http://www.w3.org/2001/XMLSchema#string

P50

Catharina C Gross

Andreas Schulte-Mecklenbeck

P577

2016-10-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27766281

http://www.w3.org/2001/XMLSchema#string

P921

multiple sclerosis

P932

5063395

http://www.w3.org/2001/XMLSchema#string